pharma · Asthma · Multiple Sclerosis · TEVA
Teva Pharma GmbH
Teva Biotech is a pharma organization headquartered in TEL AVIV, DE. It trades on NYSE under ticker TEVA. Primary therapeutic focus areas include Asthma, Multiple Sclerosis, Pain, Crohn's Disease, Seasonal Allergic Rhini
Phase 1 · mab · DLBCL
TL011 is a monoclonal antibody (mAb) developed by Teva Pharma GmbH for the treatment of diffuse large B-cell lymphoma (DLBCL), an aggressive form of non-Hodgkin lymphoma. The program completed Phase 1 clinical evaluation, with the latest milestone recorded on 22 October 2013. As a monoclonal antibody therapeutic, TL011
Internal code NHL-TL011-102
TL011 is a monoclonal antibody (mAb) developed by Teva Pharma GmbH for the treatment of diffuse large B-cell lymphoma (DLBCL), an aggressive form of non-Hodgkin lymphoma. The program completed Phase 1 clinical evaluation, with the latest milestone recorded on 22 October 2013. As a monoclonal antibody therapeutic, TL011 represents an immunological approach to DLBCL management, though the specific molecular target and mechanism of action have not been disclosed in available records. The Phase 1 trial (NCT01205737) evaluated the drug's safety, tolerability, and preliminary efficacy in DLBCL patients. Teva has not disclosed partnership arrangements, licensing terms, or plans for advancement to Phase 2 development. The program's current status beyond the 2013 milestone is not yet disclosed, and no regulatory approvals or label expansions have been announced. Peak sales projections and consensus analyst positions remain undisclosed.
Diffuse large B-cell lymphoma represents a significant unmet medical need despite advances in rituximab-based chemotherapy regimens. DLBCL remains the most common type of non-Hodgkin lymphoma, affecting thousands of patients annually worldwide, with approximately 30–40% of patients experiencing relapsed or refractory disease. Novel immunotherapeutic approaches, including monoclonal antibodies targeting B-cell antigens or tumor microenvironment components, offer potential to improve response rates and overcome chemotherapy resistance.
TL011's positioning as a mAb in DLBCL reflects the broader industry shift toward targeted biologics. The competitive landscape includes multiple Phase 3 programs from major pharmaceutical companies (Roche, AbbVie, Merck, Incyte, Regeneron, Karyopharm), indicating sustained commercial interest in this indication. However, the lack of disclosed advancement beyond Phase 1 and the absence of recent milestone updates suggest TL011 may not be actively prioritized within Teva's current oncology portfolio. The program's commercial significance depends on its differentiation from established therapies and emerging competitors, neither of which can be assessed from available data.
Drug Class: Monoclonal antibody (mAb)
Modality: Biologic; immunoglobulin-based therapeutic
Molecular Target: Not yet disclosed
Mechanism of Action: Not yet disclosed
Route of Administration: Not yet disclosed
Related Therapies: Rituximab (anti-CD20 mAb, standard of care in DLBCL); other anti-CD20 agents (obinutuzumab, ofatumumab); bispecific antibodies (mosunetuzumab, odronextamab); checkpoint inhibitors and combination regimens
First Approval: Not yet disclosed
Patent Status: Not yet disclosed
Also known as: DLBCL
Prevalence: Point prevalence: 1-5 / 10 000 (Europe) — source: Orphanet, validated.
Diffuse large B-cell lymphoma is the most common subtype of non-Hodgkin lymphoma (NHL) in adults characterized by a median age of presentation in the sixth decade of life (but also rarely occurring in adolescents and children) with the initial presentation being single or multiple rapidly growing masses (that may or may not be painful) in nodal or extranodal sites (such as thyroid, skin, breast, gastrointestinal tract, testes, bone, or brain) and that can be accompanied by symptoms of fever, night sweats and weight loss. DLBCL has an aggressive disease course, with the elderly having a poorer prognosis than younger patients, and with relapses being common.
ClinicalTrials.gov lists 606 registered studies for Diffuse, Large B-Cell, Lymphoma (AACT aggregate).
Phase breakdown: PHASE2 (204), NA (126), PHASE1 (109), PHASE1/PHASE2 (78), PHASE3 (63), EARLY_PHASE1 (9), PHASE2/PHASE3 (9), PHASE4 (8)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0018905), Orphanet — diffuse large B-cell lymphoma, NCT00022971, NCT00075478, NCT00333008, NCT00355199, NCT00386321, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
Phase 1 completion
Phase 1 trial (NCT01205737) in DLBCL completed; latest disclosed milestone.
TL011 operates within a highly competitive DLBCL therapeutic landscape dominated by Phase 3 programs from established pharmaceutical leaders. Hoffmann-La Roche is advancing MO40598 and GO39942 (both small-molecule designations, though mechanism details are not disclosed). AbbVie Deutschland is developing M22-128 and M20-621 in Phase 3. Merck Sharp and Dohme is progressing MK-2140-010, while Incyte is advancing two candidates: INCMOR 0208-305 and MOR208C310. Regeneron UK Limited is developing odronextamab (Phase 3), and Karyopharm Therapeutics is conducting XPORT-DLBCL-30 (Phase 3). Earlier-stage competitors include mosunetuzumab (Adaptive Biotechnologies, Phase 2) and lenalidomide-based combinations (Phase 2).
TL011's competitive position is unclear given the absence of disclosed mechanism, target, or clinical efficacy data. As a monoclonal antibody, it likely competes in the anti-CD20 or novel B-cell targeting space, but differentiation cannot be established from available information. The program's apparent dormancy since 2013 suggests it may not represent a priority within Teva's current oncology strategy relative to competitors' active advancement.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| MO40598 | Hoffmann-La Roche | small_molecule | phase_3 |
| COLECALCIFEROL , PREDNISONE | Fondazione Telethon ETS | small_molecule | phase_3 |
| Odronextamab | Regeneron UK Limited | small_molecule | phase_3 |
| M22-128 | AbbVie Deutschland GmbH & Co. KG | small_molecule | phase_3 |
| INCMOR 0208-305 | Incyte | small_molecule | phase_3 |
| MOR208C310 | Incyte | small_molecule | phase_3 |
| MK-2140-010 | Merck Sharp and Dohme | small_molecule | phase_3 |
| M20-621 | AbbVie Deutschland GmbH & Co. KG | small_molecule | phase_3 |
| GO39942 | Hoffmann-La Roche | small_molecule | phase_3 |
| XPORT-DLBCL-30 | Karyopharm Therapeutics Inc | small_molecule | phase_3 |
| Mosunetuzumab | Adaptive Biotechnologies Corp | small_molecule | phase_2 |
| Lenalidomide combined with G-CHOP (LO CHOP) | The First People's Hospital of Lianyungang | small_molecule | phase_2 |
| TISAGENLECLEUCEL | — | B-lymphocyte antigen CD19 binding agent | Approved |
| TAFASITAMAB | — | B-lymphocyte antigen CD19 binding agent | Approved |
| SELINEXOR | — | Exportin-1 inhibitor | Approved |
| POLATUZUMAB VEDOTIN | — | B-cell antigen receptor complex-associated protein beta chain binding agent | Approved |
| LONCASTUXIMAB TESIRINE | — | B-lymphocyte antigen CD19 binding agent | Approved |
| GLOFITAMAB | — | B-lymphocyte antigen CD20 binding agent | Approved |
| EPCORITAMAB | — | B-lymphocyte antigen CD20 binding agent | Approved |
| CRIZOTINIB | — | Hepatocyte growth factor receptor inhibitor | Approved |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
FDA Status: Not yet disclosed
EMA Status: Not yet disclosed
PMDA (Japan) Status: Not yet disclosed
NMPA (China) Status: Not yet disclosed
No regulatory approvals, breakthrough designations, fast-track designations, or orphan drug designations have been announced for TL011. The program completed Phase 1 evaluation in October 2013, but no subsequent regulatory interactions or advancement milestones have been publicly disclosed. Current regulatory pathway and development strategy remain undisclosed.
TL011 is a monoclonal antibody in development for the treatment of diffuse large B-cell lymphoma (DLBCL), an aggressive form of non-Hodgkin lymphoma.
TL011 is developed by Teva Pharma GmbH, a subsidiary of Teva Pharmaceutical Industries.
TL011 is a monoclonal antibody (mAb), a biologic therapeutic that uses the immune system to target cancer cells.
The specific mechanism of action and molecular target of TL011 have not been disclosed in available public records.
TL011 completed Phase 1 clinical evaluation in October 2013; advancement to Phase 2 or current status has not been disclosed.
No FDA approval has been announced for TL011. The program remains in development with no disclosed regulatory approvals.
TL011 was evaluated in Phase 1 trial NCT01205737 in DLBCL patients; detailed results have not been publicly reported.
No partnership or licensing arrangements have been disclosed for TL011; it appears to be developed solely by Teva Pharma GmbH.
The route of administration for TL011 has not been disclosed in available public information.
The specific molecular target of TL011 has not been disclosed; it is only identified as a monoclonal antibody for DLBCL.
Rituximab is the standard anti-CD20 monoclonal antibody for DLBCL. TL011's target and mechanism are undisclosed, preventing direct comparison of efficacy or differentiation.
Peak sales projections and commercial strategy for TL011 have not been disclosed; the program's current priority within Teva's portfolio is unclear.
Yes, multiple Phase 3 programs from Roche, AbbVie, Merck, Incyte, Regeneron, and Karyopharm are competing in DLBCL, along with earlier-stage candidates.
TL011 is being developed for patients with diffuse large B-cell lymphoma (DLBCL); specific patient subsets or lines of therapy have not been disclosed.
The first disclosure date for TL011 has not been recorded in available public information; the latest milestone is from October 2013.
The internal development code for TL011 is NHL-TL011-102, indicating a non-Hodgkin lymphoma program designation.
TL011 → Drug → Target → Indication → Company → Trials → Competitors
Development Status: TL011 appears to have stalled or been deprioritized following Phase 1 completion in 2013. The 11-year gap between the latest milestone and current date, combined with absence of Phase 2 initiation announcements, suggests the program may not be actively advancing within Teva's portfolio.
Competitive Implications: The DLBCL market has evolved significantly since 2013, with multiple bispecific antibodies, checkpoint inhibitors, and novel targeted agents now in late-stage development. TL011's lack of disclosed differentiation (target, mechanism, efficacy signals) places it at a disadvantage relative to competitors with published Phase 2/3 data and clear clinical positioning.
Strategic Considerations: Teva's oncology strategy may have shifted toward other therapeutic areas or asset priorities. The absence of partnership announcements or licensing-out activity suggests TL011 may remain internally held but inactive, or the program may have been discontinued without formal public announcement.
Future Catalysts: Potential catalysts include: (1) announcement of Phase 2 initiation or resumption; (2) disclosure of Phase 1 efficacy or biomarker data; (3) partnership or out-licensing announcement; (4) formal discontinuation statement. None of these are currently anticipated based on available information.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.